Alzheimer’s disease Diagnosis and Plasma phospho-tau217-the ADAPT study

October 15, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-10-15 Abstract: Exciting progress is being made in the early and accurate detection of Alzheimer’s disease (AD) using blood tests. The most promising of these blood markers is plasma p-tau217. Dr Ashvini Keshavan will first review the evidence for concordance of plasma p-tau217 with gold standard Alzheimer’s disease biomarkers (i.e. amyloid positron emission tomography and cerebrospinal fluid tests) and the current state of commercial availability of plasma phosphorylated tau biomarkers including comparisons of effect sizes. She will then proceed with describing the plan for ADAPT, a three-stage study including a UK multi-centre randomised controlled trial of disclosure of plasma p-tau217 results to patients and clinicians. From this study she aims to find out whether plasma p-tau217 helps to diagnose AD more quickly, more accurately and at an earlier disease stage in comparison to routine memory clinic diagnostic pathways, and we will obtain evidence for its cost effectiveness and acceptability to patients. Bio: Dr Ashvini Keshavan is a senior clinical research fellow and honorary consultant neurologist at the Dementia Research Centre, UCL Queen Square Institute of Neurology. A graduate of Trinity College, Cambridge, she completed postgraduate neurology training in London, and obtained her PhD in 2019 on Cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Her ongoing work examines these biomarkers in clinical and pre-clinical cohorts, aiming toward future application in more real-world settings, serving diverse populations. She is the joint primary investigator for the UK-wide ADAPT (Alzheimer’s disease Diagnosis and Plasma p-Tau217) study. This webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Democratising Healthcare Technology: The Role and Challenges of Participatory Design in Healthcare

September 27, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-09-27 Abstract: In this talk, Dr Stephen Lindsay will delve into the fundamental principles of participatory design, focusing on its role in democratizing the development of healthcare technologies. He will begin by exploring the core definition of participatory design, emphasizing its potential to empower users by involving them directly in the creation process. He will then contrast this approach with current Patient and Public Involvement and Engagement (PPIE) practices in the UK, highlighting how participatory design extends beyond consultation to share decision-making in design. The talk will also examine the specific challenges of applying participatory design in healthcare, navigating ethical considerations, ensuring inclusivity, and managing the complexities of working with vulnerable populations. Through case studies from his own work, he will demonstrate how participatory design can overcome these challenges, leading to more inclusive, effective, and ethically sound healthcare solutions, and offering a critical perspective on the limitations of traditional PPIE approaches. Bio: Dr Stephen Lindsay is a Lecturer in Digital Healthcare and HCI at Glasgow University. His research is cantered on participatory design, particularly with marginalized groups such as older adults, people living with dementia, and individuals with brain injuries. Dr Lindsay believes that involving these under-heard voices in healthcare technology design not only fosters more ethical practices but also drives innovation. His work has addressed diverse areas, including designing digital tools for older adults, supporting less-literate diabetes patients in rural Pakistan, and creating technologies that genuinely reflect patients’ needs and experiences. Through this approach, Dr Lindsay contributes to the development of digital health tools that are both ethically sound and practically effective, grounded in the lived experiences of those they aim to serve. This webinar is part of the 2024 Future Blood Testing Network+ webinar series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Multicorder – Enabling the Future of POC Diagnostics and Screening

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-09-12

Abstract:

Precision metabolomics and quantification for cost-effective rapid diagnosis of disease are the key goals in personalized medicine and point-of-care testing. At present, patients are subjected to multiple test procedures requiring large laboratory equipment. Here, we present a versatile single complementary metal–oxide–semiconductor chip forming a platform to address personalized needs through on-chip multimodal optical and electrochemical detection that will reduce the number of tests that patients must take. The chip integrates interleaved sensing subsystems for quadruple-mode colorimetric, chemiluminescent, surface plasmon resonance, and hydrogen ion measurements. These subsystems include a photodiode array and a single photon avalanche diode array and an array of ion sensitive field-effect transistors. The sensor arrays are distributed uniformly over an active area on the chip surface in a scalable and modular design. Bio-functionalization of the physical sensors yields a highly selective simultaneous multiple-assay platform in a disposable format. We have demonstrated its versatile capabilities through various applications such as CVD, prostate cancer diagnosis and bleeding disorders monitoring.

Bio:

Dr Chunxiao Hu is a Lecturer in Biomedical Engineering at the University of Glasgow. His research focuses on developing miniaturised portable microsystem platforms by using advanced technologies such as microfluidics, nanofabrication, surface functionalization for biomedical applications. Current projects include Highly integrated chemical sensors (electrical and optical) for multiple detection of biomarkers for early cancer diagnostics; CMOS based ISFET for fast antimicrobial susceptibility testing; Wearable biosensor for continuous monitoring of stroke; Microfluidic device for neurodegenerative diseases; Microfluidic device for electrophysiological analysis of drug uptake in nematodes.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

25/04/2024- Funding Opportunity: Technologies to enable independence for people living with dementia

The Engineering and Physical Sciences Research Council (EPSRC), in collaboration with the National Institute for Health and Care Research (NIHR), is calling for applications to develop a NetworkPlus focused on the use and development of novel tools and technologies that help people with dementia live independently.

This initiative is designed to support NetworkPlus grants that develop technologies to help people transform their care and health to become more independent at home. Networks should explore and identify the pathways and barriers to implementing these tools and technologies within the health and care system. They should also examine how technologies can be integrated into the home and coordinate care with carers and health and social care professionals, where appropriate

The role of the NetworkPlus is to nurture research ideas among its members and facilitate the transfer of knowledge to a broader community. Networks are encouraged to collaborate with a range of project partners.

🔗 To apply for this funding opportunity, visit: Technologies to enable independence for people living with dementia – UKRI

Key Dates:

  • Publication Date: 25 April 2024
  • Opening Date: 16 May 2024, 9:00am UK time
  • Closing Date: 10 September 2024, 4:00pm UK time

Eligibility and Funding Details:

  • Must be based at a UK research organisation eligible for EPSRC funding.
  • The full economic cost (FEC) of projects can be up to £2,000,000.
  • EPSRC and NIHR will fund 80% of the FEC.
  • Project duration: Up to 36 months.

To be successful, proposals need to demonstrate a clear vision, an understanding of the wider context, and the added value arising from the network. Networks should set their research focus within the UK health and social care system, with a particular interest in how tools and technologies could be realistically implemented into the current system.

Don’t miss out on this opportunity!
Apply by 10 September 2024, 4:00pm UK time.

Cyber Security Attack Impacts NHS Blood and Transplant

The recent cyber attack on Synnovis has made front-page news over the last few days due to its significant impact on pathology services at London hospitals and the subsequent increased requests for blood donors. The Future Blood Testing Network Plus has consulted researchers, Prof Carsten Maple and Dr Gregory Epiphaniou, from  the Secure Cyber Systems Research Group at WMG, University of Warwick, to gain insight into why this attack has severely affected pathology services.

A recent cyber attack has caused significant challenges for NHS Blood and Transplant leading to the organisation issuing an urgent appeal for blood donations. 

It is becoming commonplace to read or hear about a new cyber attack in the public or professional media. The UK has seen a sharp rise in severe cyber attacks, particularly those aimed at extorting money from the victim – ransomware attacks. According to the National Cyber Security Centre (NCSC), the number of ransomware attacks surged by over 27% in the past year. The NCSC received 2,005 incident reports in 2023, a 64% increase from the previous year, with 371 of these being severe enough to involve their Incident Management team (NCSC Annual Report, 2023).

Ransomware attacks have impacted a broad spectrum of sectors, from healthcare to cultural institutions such as the British Library attack in October last year.

The rise in ransomware is fuelled by a criminal ecosystem where cybercrime services can be easily procured. This allows attackers to execute ransomware attacks effectively. These criminals typically demand payments in cryptocurrencies including Bitcoin, which are difficult to trace. Even if the ransom is paid, victims may not regain access to all their files (Joint Committee on National Security Strategy, 2023).

The attack early this week on Synnovis, a pathology service provider for major London hospitals, disrupted the ability to match patient blood types. This led to an urgent appeal for O-type blood donors. O Positive blood can be given to anyone with a positive blood type, benefiting three-quarters of the population, while O Negative, known as the universal blood type, can be given to any patient (BBC News, 2024a).

The suspected perpetrators of the attack are the Qilin ransomware cyber gang, a Russian group recognised for operating a ransomware-as-a-service model over the last two years. In this instance, the attackers likely accessed Synnovis’ systems by sending phishing emails. Then, they will then have used IAX Active Directory security to increase their privilege level and propagate throughout the network. To coerce victims into paying the ransom, the Qilin gang uses double extortion, encrypting data and exfiltrating private information. The first extortion concerns requiring a payment in exchange for the decryption keys so that the victim can recover information that is encrypted, and the second requires payment to prevent release of the private information.  This latest incident is reflective of a growing pattern of attacks on the healthcare industry, with similar attacks affecting SYNLAB Italia in April 2024 and the NHS Dumfries & Galloway in March 2024.

The NHS has announced that recovery from the attack could take months, and given recent attacks that is likely to be the minimum disruption.  The impact of cyber attacks can be profound and long-lasting. The cyber attack on the British Library led to a major technology outage, causing substantial damage. This has required the installation of a new computing infrastructure, and despite efforts to restore services, disruptions persist. In November, the attackers released some of the library’s data onto the dark web, including personal user information (British Library, 2024). It is unknown which information has been captured in the Synnovis breach, but it is likely that at least some of that will be donor personal information and will be released in some way – the attackers wanting to show they will make good on their threats as a message to future victims. It is likely that as with the British Library, Synnovis and the NHS will work with NCSC to understand and recover from the attack. Despite the escalating threat, less than half of organisations have a formal ransomware plan – indeed it has recently been reported that 8% of victims have resorted to paying ransom demands (Thales, 2024).

The increase in cyber attacks underscores the urgent need for robust cybersecurity measures. Organisations need to develop comprehensive plans to address ransomware threats and invest in resilient defenses. Continuous research and investment in cybersecurity are essential to protect critical national infrastructure, maintain public trust, and ensure national security. Addressing these challenges head-on is crucial for the UK’s resilience against the evolving cyber threat landscape (Craig, 2018; Royal Society, 2022).

Authors

Prof Carsten Maple is Director of the NCSC-EPSRC Academic Centre of Excellence in Cyber Security Research and Professor of Cyber Systems Engineering at the University of Warwick. He is also a co-investigator of the PETRAS National Centre of Excellence for IoT Systems Cybersecurity, is the Research Innovation Director at EDGE-AI, the National Edge Artificial Intelligence Hub, and is a Fellow of the Alan Turing Institute.

Dr. Gregory Epiphaniou is an Associate Professor of Security Engineering at the University of Warwick, focusing on bid support, applied research, and publications. His research includes threat source characterisation and wireless communications, mainly on crypto-key generation through V-V channels. He has led and contributed to research projects worth over £20M, funded by EPSRC, IUK, and local authorities. He holds industry certifications in Information Security and has collaborated with the UK MoD. He is a subject matter expert at the Chartered Institute for Securities and Investments, a technical committee member for scientific conferences, and acted as a key member in forming the UK Cybersecurity Council WS5.

References

BBC News, 2024a. O-type blood donors needed after London cyber-attack. [online] Available at: https://www.bbc.co.uk/news/articles/c2eeg9gygyno.

British Library, 2024. British Library cyber incident review. [online] Available at: https://www.bl.uk/home/british-library-cyber-incident-review-8-march-2024.pdf.

Craig, A., 2018. Effective cyber security research can support the resilience of our digital and physical infrastructures.

Joint Committee on National Security Strategy, 2023. A hostage to fortune: ransomware and UK national security. [online] Available at: https://publications.parliament.uk/pa/jt5804/jtselect/jtnatsec/194/report.html.

NCSC Annual Review, 2023. https://www.ncsc.gov.uk/collection/annual-review-2023

Royal Society, 2022. Continuous investment in cybersecurity to counter evolving risks.

Thales, 2024. Thales data threat report reveals rise in ransomware attacks, as compliance failings leave businesses vulnerable to breaches. [online] Available at: https://www.thalesgroup.com/en/worldwide/security/press_release/2024-thales-data-threat-report-reveals-rise-ransomware-attacks.

Blood testing miniaturisation – opportunities, trends and challenges. Dr Al Edwards (University of Southampton)

May 17, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-05-17 Abstract: Although the need for better diagnostics, especially point-of-care testing, is clear, the uptake of novel technology lags a long way behind demonstration and research papers. Using several case studies from my own research, alongside insight from current state-of-the art notably in diagnostics for microbiology and infection, I will outline the technological basis for bioassay miniaturisation (i.e. tiny blood tests) and discuss the diagnostics innovation pathway. Examples will include a review of >10 years developing microfluidic quantitative multiplex immunoassays that can measure multiple biomarkers in blood, as well as our latest developments in measuring platelet cell function directly in blood. Bio: With a background in fundamental immunology combined with expertise in biochemical engineering, Al Edwards is an interdisciplinary researcher focussed on solving current and future healthcare challenges using an engineering science approach that combines a range of fields from biology, biochemistry, chemistry and physics. He works at the interface between academic technology discovery and industrial development and have experience of both fundamental research and the commercialisation of new technology. The two main challenges he currently work on are the development of affordable microfluidic technology for clinical diagnostics and microbiology, and the engineering science of complex biologic therapeutics such as vaccines. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

A Radical Solution to the Visualization and Interaction with Timeline Structured Information: UHS Lifelines Electronic Patient Record Interface

May 3, 2024 @ 12:00 pm 1:00 pm

Register for this free teams webinar here: https://futurebloodtesting.org/events/2024-05-03 Abstract: The ambitious NHS Digital Transformation Programme faces challenges in delivering efficient and intuitive information to health professionals. Since 2009, we have worked as a small team at University Hospital Southampton (UHS) Clinical Data Estate. Using e-data visualisation principles and a highly agile and iterative approach with minimal financial resources, we have developed a transformative approach to the Electronic Patient Record (EPR) interface. On UHS Lifelines, the timeframe is continuously incremental as new content accumulates. The interface opens near instantaneously in real time and documents from any time point are immediately accessible without scrolling through lists, menus, multiple frames and software subsystems, and the clinical history can be read subliminally to a valuable degree from the icon patterns. Despite initial constraints, the system evolved into a powerful application at the heart of UHS EPR. Additionally, it led to other software solutions, such as the SCR+ (Somerset Cancer Registry Enhanced) Multi-Disciplinary Team Module for cancer data management. We believe our approach has broad applicability beyond healthcare, potentially benefiting various sectors. We therefore appreciate all opportunities for collaboration to expand the project’s impact nationally and beyond. Bio: Mr David Rew is a Consultant General Surgeon in Southampton, Honorary Surgeon to the Faculty of Medicine of the University of Southampton and Visiting Professor in Clinical Informatics to Southampton Solent University. He served as the Editor in Chief of the European Journal of Surgical Oncology from 2003 to 2009. Since 2009, he has held the position of global Subject Chair for Medicine on the SCOPUS Content Selection Advisory Board, where he has appraised approximately 3,500 clinical journals. Mr Rew claims no specialist knowledge in haematology, blood testing or genomics, beyond being up to date with his Statutory and Mandatory blood transfusion module in the hospital virtual learning environment. ​For the past 15 years, David Rew has been the concept lead of a productive software development team at University Hospital Southampton, creating radical solutions to the electronic patient record, a whole-of-life breast cancer data set of more than 20,000 records, and a tool for the greater efficiency of cancer multidisciplinary teams, all of which systems sit at the heart of the unique University Hospital Southampton Clinical Data Estate. This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Details

Organiser

Online

Rapid Blood Tests: The Two-Year Manifesto. Dr Martin Peacock (Zimmer and Peacock Ltd)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-04-17

Abstract: Zimmer and Peacock has worked on the development and manufacture of a platform intended to translate academic blood testing assays from the lab into the clinical setting, and onto the market. At ZP, for research to be impactful and sustainable, it does need to be presented in a form factor so that it can be easily used by clinicians and patients. In this webinar and live streaming demo, ZP will show how a scientific paper can easily become a clinical product. The policy at ZP is to translate science into regulatory approved products in 2 years or less.

Bio: Martin Peacock is an industrial bioelectrochemist with over twenty years of biosensor experience, having had industrial roles from Abbott Diabetes to GSK, and solving technical challenges from continuous glucose monitoring to RNA analysis. He is a Director at Zimmer and Peacock Ltd, a company that sees sensors as a critical part of various social and commercial revolutions, such as the Internet of Things (IoT), Sensor Web, and the Invitro Diagnostics Market (IVD). With over eight years of experience in this role, he lead a team of talented scientists and engineers who partner with academia and industry to develop and manufacture innovative sensors and medical diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

Routine cellular diagnostics: A platelet perspective? Dr Chris Jones (University of Reading)

Register for this free teams webinar here: https://futurebloodtesting.org/event/2024-03-26

Abstract: The idea of conducting tests for an infectious disease on the kitchen table would have seemed unimaginable only three years ago; now, it is a routine part of life in the UK. Similarly, measuring health markers such as heart rate or blood pressure used to involve a trip to your GP’s surgery; now, they are measured by your watch.  Routine testing of cellular function may be the next step, supplying data on cellular changes that occur before the presentation of symptoms or rapidly assessing the efficacy of therapies.  Platelets play a vital role in chronic and acute cardiovascular disease but also have roles in immunity, inflammation, cancer metastasis, Alzheimer’s disease and infections, such as dengue, HIV-1, malaria, and COVID-19.  In addition, they are easily obtained from subjects or patients, making them valuable biomarkers for changes in blood vessels associated with disease, ageing or therapy. This seminar will introduce the utility of platelets as a cellular biomarker and the progress we have made in designing tests that capture the function of these cells, both in the lab and at point-of-care.

Bio: Chris Jones is an Associate Professor of the Thrombosis and Heamostasis in the school of Biological Sciences at the University of Reading. Over two decades, he has designed and employed innovative platelet function assays to provide novel insights into platelet dysfunction. His lab has also developed analysis software for platelet activation assays and employed microfluidics, open hardware and smartphone technology to develop low-cost point-of-care platelet function assays. These new technologies have led to HaemAnalytica, a soon-to-be established spinout, which will provide complete platelet function analysis for clinical trials and diagnostics.

This webinar is part of the Future Blood Testing Network+ Webinar Series. This series will feature a diverse range of speakers who are working in the areas of future blood testing and diagnostics.

The Future of Healthcare: Remote Blood Testing, Monitoring & AI

Registration Link: https://www.store.reading.ac.uk/conferences-and-events/henley-business-school/workshops/the-future-of-healthcare-remote-blood-testing-monitoring-ai

Formal Event Flyer: https://futurebloodtesting.org/fbtn2023/eventflyer

Description:

At the Future Blood Testing Network Plus, we are aiming to build a multi-disciplinary community to develop digital health technologies for remote, rapid, affordable and inclusive monitoring and personalised analytics. This two day workshop will feature speakers to discuss the future of healthcare, remote blood testing, monitoring and artificial intelligence (AI).

This event will take place at Leonardo Hotel Southampton (Formerly Jurys Inn). Both days will include lunch and coffee breaks, with day 1 also including a drinks reception with dinner.

NB: Due to venue policies on final numbers we cannot guarantee that we can cater to all dietary requirements after the 12th October. 

Event Costs

  • £30 – Physical Day Attendance (Includes lunch on both days, and dinner and drinks on day 1)
  • £50 – Accommodation (per night – Bed and Breakfast available on the 6th and 7th November)

Draft Agenda

Day 1 – 7th November

  • 10:00-10:30: Coffee & Registration
  • 10:30-12:00: Session 1: Landscape of Future Blood Testing – Session Chair: Dr Samantha Pearman-Kanza (University of Southampton)
    • 10:30-11:00: Future Blood Testing Network+ Overview and RecapProfessor Weizi (Vicky) Li (University of Reading)
    • 11:00-11:30: Remote Testing & AI – What’s Coming NextMr Frank Khan Sullivan (Enhanced Fertility)
    • 11:30-12:00: Landscape of Future blood testing in healthcare practice – Professor Dimitris Grammatopoulos (University of Warwick)
  • 12:00-13:00: Lunch & Photo session
  • 13:00-15:00: Session 2: Network Funded Projects  – Session Chair: Prof Weizi (Vicky) Li (University of Reading)
    • 13:00-13:30: Multi-modal deep learning approaches for identification of prognostic and diagnostic biomarkersDr Heba Sailem (Kings College London)
    • 13:30-14:00: FERRIQ: AI-Driven mapping of disease trajectories of patients with genetic iron overload to inform development of clinical decision support systemsDr Fayyaz Minhas & Professor Dimitris Grammatopoulos (University of Warwick)
    • 14:00-14:15: Development of an implantable device for continuous monitoring of blood biomarkersDr Chenyang He (University of Nottingham)
    • 14:15-14:30: Blood microfluidics for point of care diagnosticsProfessor Stavroula Balabani (UCL)
    • 14:30-14:45: Raman spectroscopy for remote blood testing – Dr Donna Arnold (University of Kent)
    • 14:45-15:00: Wearable Otological Measurement of Blood Analytes (WOMBA) – Dr Peter J. Christopher (University of Nottingham)
  • 15:00-15:15: Coffee Break
  • 15:15-17:15: Session 3: Adoption & Design for the Future of Digital Healthcare & Diagnostics: Design, data, NHS adoption and commercialisation
    • 15:15-15:30: Information Design in medical testingProfessor Sue Walker (University of Reading)
    • 15:30-17:15: Round Table (facilitated by Al, Sue, Mamta, Age)
      • Design: Professor Sue Walker (University of Reading)
      • Data: Professor Age Chapman (University of Southampton)
      • NHS adoption: Dr Mamta Bajre (Oxford Academic Health Science Network)
      • Commercialisation: Associate Professor Alexander Edwards (University of Southampton)
  • 17:10-17:30: Wrap Up
  • 17:30-19:00: Drinks Reception & Networking
  • 19:00: Conference Dinner

Day 2 – 8th November

  • 09:30-09:55: Coffee
  • 09:55-10:00: Welcome BackProfessor Weizi (Vicky) Li (University of Reading)
  • 10:00-12:30: Session 4: Future Blood Testing Research – Chair: Dr Mark Elliott (University of Warwick)
    • 10:00-10:30: Translating blood tests from the Academic Lab into the Clinical Setting – a Case StudyDr Martin Peacock (Zimmer and Peacock Ltd)
    • 10:30-11:00: An immune score based on longitudinal blood testingDr Hector Zenil (Oxford Immune Algorithmics)
    • 11:00-11:30: Coffee Break
    • 11:30-12:00: Detection of drugs and biomarkers in healthcare using optical fibre sensorsProfessor Serhiy Korposh (University of Nottingham)
    • 12:00-12:30: Squishing Biology to Advance Healthcare: A Journey from Saliva to Blood
      Dr Robert Barker (University of Kent)
  • 12:30-13:30: Lunch